COMPANY:

Stella Diagnostics

"ProPhase Labs...announced it has completed its previously announced acquisition of the world-wide exclusive rights to the BE-Smart Esophageal Pre-Cancer diagnostic screening test and related intellectual property assets from Stella Diagnostics, Inc. ('Stella')."

"ProPhase Labs...today announced that it has entered into an asset purchase agreement to acquire from Stella Diagnostics, Inc. ('Stella') world-wide exclusive rights to Stella’s BE-Smart Esophageal Pre-Cancer diagnostic screening test and related intellectual property assets for approximately $4.5 million dollars, comprised of approximately $3.5 million in cash and $1 million in ProPhase common stock."

"Stella Diagnostics, Inc...announced today that its abstract titled 'Markers in STLA101 Assay Detects Differential Expression to Distinguish Between Intramucosal and Invasive Esophageal Adenocarcinoma' has been selected for presentation during Digestive Disease Week (DDW) 2022, which will take place May 21–24, 2022 at the San Diego Convention Center in San Diego, CA."

"Stella Diagnostics, Inc...announced it will be giving a data presentation this week at the American Association for Cancer Research (AACR) Annual Meeting, which is being held April 8 – 13, 2022, at the Ernest N. Morial Convention Center in New Orleans, LA."

“Stella Diagnostics…announced today that they have entered into a partnership with mProbe…to build, optimize and further validate Stella's novel panel of proteomic biomarkers designed to detect and quantify proto-oncogenes present in precancerous esophageal tissues. mProbe's CAP-accredited and CLIA-certified laboratory in Maryland has performed landmark research with a focus on transforming the field of Precision Medicine, Precision Health, and Predictive Healthcare Analytics utilizing its cutting-edge proprietary multi-omics platform.”